Transgene SA (FR:TNG)
:TNG
TNG Stock Chart & Stats
€0.94
<€0.01(0.40%)
At close: 4:00 PM EST
€0.94
<€0.01(0.40%)
Day’s Range― - ―
52-Week Range€0.53 - €1.50
Previous CloseN/A
Volume15.92K
Average Volume (3M)129.86K
Market Cap
€202.69M
Enterprise Value€102.11M
Total Cash (Recent Filing)€111.86M
Total Debt (Recent Filing)€2.06M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Apr 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding274,186,700
10 Day Avg. Volume204,663
30 Day Avg. Volume129,863
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)1.14
Price to Sales (P/S)1011.31
P/FCF Ratio-3.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€10.17M
Bulls Say, Bears Say
Bulls Say
Balance Sheet & RunwayThe December 2025 EUR 105m raise and EUR 39m debt conversion materially strengthened liquidity and left Transgene with minimal leverage. This improved capitalization provides financial visibility into early 2028, lowering near-term financing risk, enabling continued R&D and GMP investments and preserving partnering optionality over the medium term.
TG4050 Phase I EfficacyTG4050's 100% disease-free survival in the treated Phase I cohort (≥2 years) is a strong early efficacy signal. If replicated in the randomized Phase II readout, this outcome would materially de-risk the neoantigen platform, improve regulatory dialogue and increase the probability of attractive partnership or commercialization paths over the next 2–4 years.
Durable ImmunogenicitySustained neoantigen-specific T-cell responses in 73% of evaluable patients with 24-month persistence demonstrate biological durability aligned with the product's mechanism. Durable immune responses increase the likelihood of lasting clinical benefit, strengthen scientific credibility, and enhance the asset's appeal to partners and payers over the longer development horizon.
Bears Say
Cash Burn & Weak Cash FlowTransgene reported negative operating cash flow (~EUR -36.7m in 2025) and ongoing negative free cash flow, meaning operations consume cash rather than generate it. Even with current runway into early 2028, persistent cash burn implies reliance on future financings or partnerships, creating dilution and execution risk beyond the near term.
Manufacturing Timeline RiskTargeting full GMP readiness by Q3 2027 creates a long lead-time before the company can support large pivotal trials or commercialization. This operational timing risk can delay trial starts, limit supply for partnerships, increase costs and complicate regulatory or deal timelines, constraining near- to mid-term value realization.
Readout Immaturity & Field DependenceKey efficacy endpoints (2-year DFS for the randomized Phase II) are not yet mature and Phase I data are still under peer review. The company's prospects thus hinge on forthcoming binary clinical readouts and broader INTV field validation, exposing the business to outcome-driven swings in partner interest and regulatory momentum.
Transgene News
TNG FAQ
What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest stock price was €0.53 and its highest was €1.50 in the past 12 months.
What is Transgene SA’s market cap?
Transgene SA’s market cap is €202.69M.
When is Transgene SA’s upcoming earnings report date?
Transgene SA’s upcoming earnings report date is Apr 29, 2026 which is in 24 days.
How were Transgene SA’s earnings last quarter?
Transgene SA released its earnings results on Mar 24, 2026. The company reported -€0.114 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.114.
Is Transgene SA overvalued?
According to Wall Street analysts Transgene SA’s price is currently Overvalued.
Does Transgene SA pay dividends?
Transgene SA does not currently pay dividends.
What is Transgene SA’s EPS estimate?
Transgene SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene SA have?
Transgene SA has 274,186,700 shares outstanding.
What happened to Transgene SA’s price movement after its last earnings report?
Transgene SA reported an EPS of -€0.114 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.541%.
Which hedge fund is a major shareholder of Transgene SA?
Currently, no hedge funds are holding shares in FR:TNG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Transgene SA
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―